Myeloid-derived suppressor cells and their role in gynecological malignancies

Myeloid-derived suppressor cells are a heterogeneous population of immature myeloid cells that exhibit immunosuppressive activity (they block the proliferation and activity of both T cells and natural killer cells). In addition to their role in suppressing immune responses, myeloid-derived suppressor cells directly stimulate tumor cell proliferation, metastasis, and angiogenesis. In the area of gynecological cancer, increased numbers of circulating myeloid-derived suppressor cells or tumor-infiltrating myeloid-derived suppressor cells have been detected, and the increased frequencies of myeloid-derived suppressor cells are associated with a poor prognosis. Thus, the successful myeloid-derived suppressor cells depletion may hold the key to maximizing existing anti-cancer therapies and improving the prognosis of gynecological cancer. In this review, we summarize current knowledge regarding myeloid-derived suppressor cells biology, clinical significance of myeloid-derived suppressor cells, and the potential myeloid-derived suppressor cells–targeting strategies in gynecological cancer.

[1]  Amanda R. Campbell,et al.  Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor–Mediated Natural Killer Cell Function , 2018, Clinical Cancer Research.

[2]  S. Mabuchi,et al.  PM01183 inhibits myeloid-derived suppressor cells in vitro and in vivo. , 2017, Immunotherapy.

[3]  L. Bu,et al.  Targeting phosphorylation of STAT3 delays tumor growth in HPV-negative anal squamous cell carcinoma mouse model , 2017, Scientific Reports.

[4]  M. Caligiuri,et al.  Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer , 2017, Cancer Immunology, Immunotherapy.

[5]  G. Ullenhag,et al.  Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer , 2016, Journal of Translational Medicine.

[6]  N. Matsumura,et al.  Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells , 2016, Clinical Cancer Research.

[7]  Peter J. Murray,et al.  Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards , 2016, Nature Communications.

[8]  J. Wolchok,et al.  Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors , 2016, EBioMedicine.

[9]  M. Schell,et al.  Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab , 2016, Cancer Immunology Research.

[10]  Yang Zhao,et al.  mTOR masters monocytic myeloid-derived suppressor cells in mice with allografts or tumors , 2016, Scientific Reports.

[11]  D. Schadendorf,et al.  Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab , 2016, Clinical Cancer Research.

[12]  A. Krüger,et al.  The induction of human myeloid derived suppressor cells through hepatic stellate cells is dose-dependently inhibited by the tyrosine kinase inhibitors nilotinib, dasatinib and sorafenib, but not sunitinib , 2016, Cancer Immunology, Immunotherapy.

[13]  E. Morii,et al.  The significance of G-CSF expression and myeloid-derived suppressor cells in the chemoresistance of uterine cervical cancer , 2015, Scientific Reports.

[14]  D. Gabrilovich,et al.  Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. , 2015, The Journal of clinical investigation.

[15]  G. Freeman,et al.  Combination cancer immunotherapy and new immunomodulatory targets , 2015, Nature Reviews Drug Discovery.

[16]  S. Goodman,et al.  Tadalafil Augments Tumor Specific Immunity in Patients with Head and Neck Squamous Cell Carcinoma , 2015, Clinical Cancer Research.

[17]  L. Ellis,et al.  Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models , 2014, Cancer Immunology Research.

[18]  M. Nagarkatti,et al.  Deficiency of Kruppel-like factor KLF4 in myeloid-derived suppressor cells inhibits tumor pulmonary metastasis in mice accompanied by decreased fibrocytes , 2014, Oncogenesis.

[19]  M. Sade-Feldman,et al.  Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes. , 2014, Cancer research.

[20]  A. Alimonti,et al.  Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer , 2014, Nature.

[21]  K. Kinzler,et al.  Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells , 2014, Journal of Immunotherapy for Cancer.

[22]  E. Morii,et al.  Uterine cervical cancer displaying tumor-related leukocytosis: a distinct clinical entity with radioresistant feature. , 2014, Journal of the National Cancer Institute.

[23]  V. Bronte,et al.  Myeloid‐derived suppressor cell heterogeneity in human cancers , 2014, Annals of the New York Academy of Sciences.

[24]  F. Amant,et al.  Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy , 2014, Cancer Immunology, Immunotherapy.

[25]  D. Schadendorf,et al.  Vemurafenib reverses immunosuppression by myeloid derived suppressor cells , 2013, International journal of cancer.

[26]  J. Talmadge,et al.  History of myeloid-derived suppressor cells , 2013, Nature Reviews Cancer.

[27]  R. Nurieva,et al.  Generation of a novel therapeutic peptide that depletes MDSC in tumor-bearing mice , 2013, Nature Medicine.

[28]  Kathleen R. Cho,et al.  Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. , 2013, Immunity.

[29]  P. Newell,et al.  The Peripheral Myeloid Expansion Driven by Murine Cancer Progression Is Reversed by Radiation Therapy of the Tumor , 2013, PloS one.

[30]  J. Markowitz,et al.  Myeloid derived suppressor cells – a new therapeutic target in the treatment of cancer , 2013, Journal of Immunotherapy for Cancer.

[31]  Stephen Mok,et al.  CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. , 2013, Cancer research.

[32]  Dung-Tsa Chen,et al.  Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer , 2013, Cancer Immunology, Immunotherapy.

[33]  H. Zhang,et al.  STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. , 2013, The Journal of clinical investigation.

[34]  Pieter Wesseling,et al.  The immunosuppressive tumour network: myeloid‐derived suppressor cells, regulatory T cells and natural killer T cells , 2013, Immunology.

[35]  S. Ponnazhagan,et al.  Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer. , 2013, Cancer research.

[36]  Yulia Nefedova,et al.  Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer , 2012, Nature Immunology.

[37]  S. Terada,et al.  Anti‐IL‐6 receptor mAb eliminates myeloid‐derived suppressor cells and inhibits tumor growth by enhancing T‐cell responses , 2012, European journal of immunology.

[38]  R. Kiessling,et al.  Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines , 2012, Cancer Immunology, Immunotherapy.

[39]  A. Guglielmotti,et al.  Targeting monocyte chemotactic protein-1 synthesis with bindarit induces tumor regression in prostate and breast cancer animal models , 2012, Clinical & Experimental Metastasis.

[40]  Daniel G. Anderson,et al.  Origins of tumor-associated macrophages and neutrophils , 2012, Proceedings of the National Academy of Sciences.

[41]  K. Odunsi,et al.  PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. , 2011, Cancer research.

[42]  G. Lesinski,et al.  Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. , 2011, Cancer research.

[43]  B. Rini,et al.  MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. , 2011, International immunopharmacology.

[44]  Karin Jirström,et al.  Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. , 2011, Cancer discovery.

[45]  E. Tartour,et al.  Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy , 2011, Cancer and Metastasis Reviews.

[46]  T. Padhya,et al.  HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment , 2010, The Journal of experimental medicine.

[47]  H. Hoogsteden,et al.  COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function , 2010, BMC Cancer.

[48]  D. Gilvary,et al.  A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers , 2010, Clinical Cancer Research.

[49]  O. Arrieta,et al.  Randomized phase II trial of All-trans-retinoic acid with chemotherapy based on paclitaxel and cisplatin as first-line treatment in patients with advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  D. Mougiakakos,et al.  Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. , 2010, Cancer research.

[51]  B. Rini,et al.  Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. , 2010, Cancer research.

[52]  J. Vincent,et al.  5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. , 2010, Cancer research.

[53]  M. Sporn,et al.  Anti-inflammatory Triterpenoid Blocks Immune Suppressive Function of MDSCs and Improves Immune Response in Cancer , 2010, Clinical Cancer Research.

[54]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[55]  K. Chamoto,et al.  Potential differentiation of tumor bearing mouse CD11b+Gr-1+ immature myeloid cells into both suppressor macrophages and immunostimulatory dendritic cells. , 2009, Biomedical research.

[56]  Hua Yu,et al.  Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. , 2008, The Journal of clinical investigation.

[57]  J. Talmadge,et al.  Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. , 2008, Blood.

[58]  C. Chuang,et al.  Pretreatment with Cisplatin Enhances E7-Specific CD8+ T-Cell–Mediated Antitumor Immunity Induced by DNA Vaccination , 2008, Clinical Cancer Research.

[59]  D. Carbone,et al.  Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. , 2008, Cancer cell.

[60]  Z. Werb,et al.  Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. , 2007, Cancer research.

[61]  M. Fishman,et al.  Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. , 2007, Cancer research.

[62]  J. Califano,et al.  Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function , 2006, The Journal of experimental medicine.

[63]  Paolo Serafini,et al.  Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. , 2006, Seminars in cancer biology.

[64]  L. Kaiser,et al.  Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity , 2005, Clinical Cancer Research.

[65]  M. Baniyash.  TCR ζ-chain downregulation: curtailing an excessive inflammatory immune response , 2004, Nature Reviews Immunology.

[66]  Joseph I. Clark,et al.  Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3 , 2004, Cancer Immunology, Immunotherapy.

[67]  George Coukos,et al.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.

[68]  H. Schreiber,et al.  Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[69]  M. Nishimura,et al.  Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy , 2008, Cancer Immunology, Immunotherapy.

[70]  M. Colombo,et al.  The terminology issue for myeloid-derived suppressor cells. , 2007, Cancer research.

[71]  S. Strober.  Natural suppressor (NS) cells, neonatal tolerance, and total lymphoid irradiation: exploring obscure relationships. , 1984, Annual review of immunology.